Business
Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies
Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nResverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nResverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies\nCanada NewsWire\nCALGARY, Nov. 17, 2016\n\n\n\nThe successful completion of this Phase 1 pharmacokinetic (PK) trial in patients with severe renal impairment clears the path for the Company to further expand its previously announced Renal and Orphan programs\n\n\n\nCALGARY, Nov. 17, 2016 /CNW/ - Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX:RVX) today announced the collection of successful data from the New Zealand based Phase 1 PK study with lead drug candidate apabetalone in patients with severe renal impairment. \n\nResverlogix was able to confirm its primary objective of the Phase 1 study by demonstrating that apabetalone treated patients with severe renal impairment have the same favorable PK traits and safety profile as has been observed in previous apabetalone trials.  These results will allow the Company to proceed with more advanced renal impairment and dialysis trials. The study also explored acute changes in biomarkers relevant to Bromodomain and Extra-Terminal (BET) inhibition in subjects with severe renal impairment, the data for which is still under analysis. Two cohorts, each comprised of eight subjects, were evaluated in the study. Cohort one included subjects with end-stage renal disease (ESRD) not on dialysis, with an estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73m2 (normal eGFR range > 90 mL/min/1.73m2) while cohort two included healthy individuals whose age, weight and gender were matched to the renal impaired subjects. \n\nThe Company's Phase 3 BETonMACE trial, designed for high-risk cardiovascular disease patients with type 2 diabetes and low high-density lipoprotein (HDL), continues enrollment as planned.  The Company now plans to initiate a Phase 2 Renal Impairment trial that is expected to commence in early 2017 based on the PK data confirmed...